United States: FDA Approves BMS And J&J CAR-T Cell Therapies For The Earlier Treatment Of Multiple Myeloma - Goodwin Procter LLP

On April 4, 2024, Bristol Myers Squibb ("BMS") and 2seventy bio, Inc. announced that the FDA has approved ABECMA (idecabtagene vicleucel) for the treatment of adult patients with relapsed ...